{
    "organizations": [],
    "uuid": "28be947fc3e798889f323664c8433d25db820dfe",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/23/globe-newswire-geovax-reports-2017-year-end-financial-results.html",
    "ord_in_thread": 0,
    "title": "GeoVax Reports 2017 Year-End Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "ATLANTA, March 23, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2017.\nGeoVax reported grant and collaboration revenues of $1.1 million for 2017, as compared to $0.8 million in 2016. Research and development (R&D) expenses were $2.0 million in 2017, compared with $2.0 million in 2016. General and administrative (G&A) expenses were $1.2 million in 2017, compared to $2.1 million in 2016.\nNet loss for the year ended December 31, 2017 of $2.2 million, or $0.03 per share, based on 68.6 million weighted average shares outstanding. For the year ended December 31, 2016, the Company reported a loss of $3.3 million, or $0.08 per share, based on 41.5 million weighted average shares outstanding.\nRobert McNally, PhD, President and CEO, commented, “During the past year, GeoVax made solid progress with its HIV human clinical program, built on its proof-of-concept in animal models for HIV, Zika, Ebola and Lassa vaccines, expanded its infectious disease targets to chronic hepatitis B (therapeutic) and malaria, while simultaneously showing promising results in solid tumor immuno-oncology models. I look forward to soon providing our shareholders and other interested parties with a more detailed update on our various development programs.”\nSummarized financial information is attached. Further information concerning the Company’s financial position and results of operations are included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission.\nAbout GeoVax\nGeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company’s development programs are focused on preventive vaccines against HIV, Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. visit www.geovax.com .\nContact:\nRobert T. McNally, Ph.D.\nGeoVax Labs, Inc.\ninvestor@geovax.com\n678-384-7220\nFINANCIAL TABLES FOLLOW\nGEOVAX LABS, INC. Condensed Consolidated Statements of Operations Information (amounts in thousands, except per share data) Year Ended December 31, 2017 2016 Grant and collaboration revenue $ 1,075 $ 828 Operating expenses: Research and development 2,017 1,971 General and administrative 1,232 2,131 3,249 4,102 Loss from operations (2,174 ) (3,274 ) Interest income 4 2 Net loss $ (2,170 ) $ (3,272 ) Net loss per common share $ (0.03 ) $ (0.08 ) Weighted average shares outstanding 68,606 41,517\nCondensed Consolidated Balance Sheet Information (amounts in thousands) December 31, 2017 2016 Assets: Cash and cash equivalents $ 313 $ 454 Other current assets 135 90 Total current assets 448 544 Property, net 31 55 Other assets 11 11 Total assets $ 490 $ 610 Liabilities and stockholders’ equity Current liabilities $ 811 $ 370 Stockholders’ equity (deficiency) (321 ) 240 Total liabilities and stockholders’ equity $ 490 $ 610 Common Shares Outstanding 106,737 55,235\nSource:GeoVax, Inc.",
    "published": "2018-03-23T23:00:00.000+03:00",
    "crawled": "2018-03-24T00:42:24.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "atlanta",
        "march",
        "globe",
        "newswire",
        "geovax",
        "lab",
        "otcqb",
        "govx",
        "biotechnology",
        "company",
        "developing",
        "innovative",
        "human",
        "vaccine",
        "using",
        "novel",
        "platform",
        "technology",
        "today",
        "announced",
        "financial",
        "result",
        "year",
        "ended",
        "december",
        "geovax",
        "reported",
        "grant",
        "collaboration",
        "revenue",
        "million",
        "compared",
        "million",
        "research",
        "development",
        "r",
        "expense",
        "million",
        "compared",
        "million",
        "general",
        "administrative",
        "g",
        "expense",
        "million",
        "compared",
        "million",
        "net",
        "loss",
        "year",
        "ended",
        "december",
        "million",
        "per",
        "share",
        "based",
        "million",
        "weighted",
        "average",
        "share",
        "outstanding",
        "year",
        "ended",
        "december",
        "company",
        "reported",
        "loss",
        "million",
        "per",
        "share",
        "based",
        "million",
        "weighted",
        "average",
        "share",
        "outstanding",
        "robert",
        "mcnally",
        "phd",
        "president",
        "ceo",
        "commented",
        "past",
        "year",
        "geovax",
        "made",
        "solid",
        "progress",
        "hiv",
        "human",
        "clinical",
        "program",
        "built",
        "animal",
        "model",
        "hiv",
        "zika",
        "ebola",
        "lassa",
        "vaccine",
        "expanded",
        "infectious",
        "disease",
        "target",
        "chronic",
        "hepatitis",
        "b",
        "therapeutic",
        "malaria",
        "simultaneously",
        "showing",
        "promising",
        "result",
        "solid",
        "tumor",
        "model",
        "look",
        "forward",
        "soon",
        "providing",
        "shareholder",
        "interested",
        "party",
        "detailed",
        "update",
        "various",
        "development",
        "summarized",
        "financial",
        "information",
        "attached",
        "information",
        "concerning",
        "company",
        "financial",
        "position",
        "result",
        "operation",
        "included",
        "annual",
        "report",
        "form",
        "filed",
        "security",
        "exchange",
        "commission",
        "geovax",
        "geovax",
        "lab",
        "biotechnology",
        "company",
        "developing",
        "human",
        "vaccine",
        "infectious",
        "disease",
        "using",
        "modified",
        "vaccinia",
        "like",
        "particle",
        "vaccine",
        "platform",
        "company",
        "development",
        "program",
        "focused",
        "preventive",
        "vaccine",
        "hiv",
        "zika",
        "virus",
        "hemorrhagic",
        "fever",
        "virus",
        "ebola",
        "sudan",
        "marburg",
        "lassa",
        "malaria",
        "well",
        "therapeutic",
        "vaccine",
        "chronic",
        "hepatitis",
        "b",
        "infection",
        "cancer",
        "geovax",
        "vaccine",
        "platform",
        "support",
        "vivo",
        "production",
        "vlps",
        "cell",
        "person",
        "receiving",
        "vaccine",
        "mimicking",
        "natural",
        "infection",
        "stimulating",
        "humoral",
        "cellular",
        "arm",
        "immune",
        "system",
        "recognize",
        "prevent",
        "control",
        "target",
        "infection",
        "visit",
        "contact",
        "robert",
        "mcnally",
        "geovax",
        "lab",
        "investor",
        "financial",
        "table",
        "follow",
        "geovax",
        "lab",
        "condensed",
        "consolidated",
        "statement",
        "operation",
        "information",
        "amount",
        "thousand",
        "except",
        "per",
        "share",
        "data",
        "year",
        "ended",
        "december",
        "grant",
        "collaboration",
        "revenue",
        "operating",
        "expense",
        "research",
        "development",
        "general",
        "administrative",
        "loss",
        "operation",
        "interest",
        "income",
        "net",
        "loss",
        "net",
        "loss",
        "per",
        "common",
        "share",
        "weighted",
        "average",
        "share",
        "outstanding",
        "condensed",
        "consolidated",
        "balance",
        "sheet",
        "information",
        "amount",
        "thousand",
        "december",
        "asset",
        "cash",
        "cash",
        "equivalent",
        "current",
        "asset",
        "total",
        "current",
        "asset",
        "property",
        "net",
        "asset",
        "total",
        "asset",
        "liability",
        "stockholder",
        "equity",
        "current",
        "liability",
        "stockholder",
        "equity",
        "deficiency",
        "total",
        "liability",
        "stockholder",
        "equity",
        "common",
        "share",
        "outstanding",
        "source",
        "geovax",
        "inc"
    ]
}